Keyword: Sanford C Bernstein
Big Pharma's emerging markets sales growth plunged to a new low last quarter. But within the group's overall average, some companies--such as AstraZeneca and Pfizer--chalked up decent gains.
Analysts hiked their estimates for Merck & Co.’s Keytruda sales last week after a Bristol-Myers Squibb rival fell short in a key lung cancer study. But if new doctor surveys prove out, they may need to jack up those estimates even more.
Merck & Co. just scored a point in its immuno-oncology rivalry against Bristol-Myers Squibb. The PD-1 med Keytruda beat chemo in previously untreated lung cancer patients, staving off cancer growth and extending patients’ lives.
Investors have been salivating for years over the prospect of Pfizer splitting into two separate companies, and now, decision day is looming. What happens if CEO Ian Read's answer is No?